Full Press Release Details
Announces Financial Results for the First Quarter Ended March 31, 2025
LAKE CITY, May 8, 2025 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform
to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2025
and provided a corporate update.
| Lipocine has initiated an outpatient Phase 3 safety and efficacy study of LPCN 1154, a non-invasive, rapid onset, oral formulation of brexanolone for the treatment of postpartum depression (PPD). Dosing of the first patient is anticipated in the second quarter of 2025. The Phase 3 study is expected to support a 505(b)(2) New Drug Application (NDA) submission in 2026. | |
| Lipocine is exploring the possibility of partnering LPCN 1154 with a third party. |
2401 for Obesity Management
| LPCN 2401 is targeted to be a once daily oral formulation comprising a proprietary anabolic androgen receptor agonist. It is expected to have a favorable benefit to risk profile as a non-invasive option for use as an adjunct to GLP-1 receptor agonist therapies and/or as a monotherapy post cessation of GLP-1 receptor agonist therapies with demonstrated benefits to the liver. | |
| Based on a pre-IND meeting and 2025 FDA draft guidance on Obesity and Overweight, the FDA recommends identifying the appropriate patient population for treatment, and also recommends that an approvable endpoint would be one that measures how a patient feels, functions, or survives. Therefore, in an upcoming proof-of-concept study of LPCN 2401 as an adjunct to GLP-1 agonist, Lipocine plans to target the elderly patient population, reportedly the population most vulnerable to lean mass and functionality loss while on GLP-1 agonist treatment, with plans to include functionality measures. | |
| Lipocine is exploring the possibility of partnering LPCN 2401 with a third party. |
| Lipocine has an exclusive License Agreement with Verity Pharma (Verity), entered into in 2024, under which Verity has the rights to market TLANDO, its oral testosterone replacement therapy, in the United States and Canada, if approved. | |
| In April 2025, Lipocine entered into a license and supply agreement with Ach granting exclusive rights to market TLANDO in Brazil. Ach is a Brazilian pharmaceutical company founded nearly 60 years ago with a mission to improve people's lives. Today, Ach 's products reach more than 20 countries across Latin America, Africa, Asia, and Europe, in addition to its home base in Brazil. | |
| Lipocine continues to explore partnering TLANDO in territories outside the U.S., Canada, South Korea, the GCC countries and Brazil. |
Quarter Ended March 31, 2025, Financial Results
of March 31, 2025, Lipocine had $19.7 million of unrestricted cash, cash equivalents and marketable investment securities compared to
$21.6 million at December 31, 2024.
reported a net loss of $1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025, compared with net income of
$3.5 million, or $0.66 per diluted share, for the quarter ended March 31, 2024.
company recognized royalty revenue from TLANDO sales of $94,000 during the quarter ended March 31, 2025, compared to royalty revenue
of $117,000 during the quarter ended March 31, 2024. No license revenue was recognized during the quarter ended March 31, 2025, compared
to $7.5 million in the quarter ended March 31, 2024. The license revenue in 2024 resulted from our license with Verity.
and development expenses were $1.1 million and $2.8 million, respectively, for the quarters ended March 31, 2025 and 2024. The decrease
in research and development expenses was primarily a result of a decrease in costs related to our LPCN 1154 clinical studies in 2025
as compared to 2024, a decrease related to the wind down of our LPCN 1148 study in 2024, and a decrease in TLANDO related costs in 2025.
These were offset by an increase in other research and development related costs and supplies in 2025.
and administrative expenses were $1.1 million and $1.6 million, respectively, for the quarters ended March 31, 2025 and 2024. The decrease
in general and administrative expenses primarily consisted of a decrease related to the one-time business development fees incurred in
2024 in conjunction with the Verity Pharmaceutical license agreement.
is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. Lipocine
has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent
enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable
markets with significant unmet medical needs.
clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101
for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral
proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in
obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms
associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm
birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated
cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral
prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with
a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product candidates and related clinical
trials, our development of our product candidates and related efforts with the FDA, including with respect to LPCN 1154, our P3 safety
and efficacy study relating to LPCN 1154, the timing and potential results of the safety and efficacy study relating to LPCN 1154, potential
partnering of our product candidates with third parties, and the potential uses and benefits of our product candidates. Investors are
cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we
may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for
our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into
partnerships or other strategic relationships to monetize our non-core assets, safety and efficacy studies, including those relating
to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any
of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and
plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt
of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials,
patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks
detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q,
all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any
forward-looking statements contained in this release, except as required by law.
further information:
INC. AND SUBSIDIARIES
Consolidated Balance Sheets
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,354,596 | $ | 6,205,926 | ||||
| Marketable investment securities | 16,364,050 | 15,427,385 | ||||||
| Accrued interest income | 179,027 | 120,447 | ||||||
| Prepaid and other current assets | 428,795 | 567,915 | ||||||
| Total current assets | 20,326,468 | 22,321,673 | ||||||
| Property and equipment, net of accumulated depreciation of $1,238,867 and $1,223,297 respectively | 149,505 | 165,075 | ||||||
| Other assets | 23,753 | 23,753 | ||||||
| Total assets | $ | 20,499,726 | $ | 22,510,501 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 360,239 | $ | 271,696 | ||||
| Accrued expenses | 619,410 | 921,240 | ||||||
| Deferred revenue | 320,000 | 320,000 | ||||||
| Total current liabilities | 1,299,649 | 1,512,936 | ||||||
| Total liabilities | 1,299,649 | 1,512,936 | ||||||
| Stockholders' equity: | ||||||||
| Common stock, par value $0.0001 per share, 200,000,000 shares authorized; 5,350,692 and 5,348,276 issued and 5,350,356 and 5,347,940 outstanding, respectively | 8,863 | 8,863 | ||||||
| Additional paid-in capital | 220,860,140 | 220,789,138 | ||||||
| Treasury stock at cost, 336 shares | (40,712 | ) | (40,712 | ) | ||||
| Accumulated other comprehensive income | 5,521 | 9,138 | ||||||
| Accumulated deficit | (201,633,735 | ) | (199,768,862 | ) | ||||
| Total stockholders' equity | 19,200,077 | 20,997,565 | ||||||
| Total liabilities and stockholders' equity | $ | 20,499,726 | $ | 22,510,501 |
INC. AND SUBSIDIARIES
Consolidated Statements of Operations and Comprehensive Income (Loss)
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenues: | ||||||||
| License revenue | $ | - | $ | 7,500,000 | ||||
| Royalty revenue | 93,864 | 117,174 | ||||||
| Total revenues | 93,864 | 7,617,174 | ||||||
| Operating expenses: | ||||||||
| Research and development | 1,061,571 | 2,818,926 | ||||||
| General and administrative | 1,122,477 | 1,575,719 | ||||||
| Total operating expenses | 2,184,048 | 4,394,645 | ||||||
| Operating income (loss) | (2,090,184 | ) | 3,222,529 | |||||
| Other income: | ||||||||
| Interest and investment income | 225,511 | 331,364 | ||||||
| Unrealized loss on warrant liability | - | (40,072 | ) | |||||
| Total other income | 225,511 | 291,292 | ||||||
| Income (loss) before income tax expense | (1,864,673 | ) | 3,513,821 | |||||
| Income tax expense | (200 | ) | (200 | ) | ||||
| Net income (loss) attributable to common shareholders | $ | (1,864,873 | ) | $ | 3,513,621 | |||
| Basic earnings (loss) per share attributable to common stock | $ | (0.35 | ) | $ | 0.66 | |||
| Weighted average common shares outstanding, basic | 5,348,557 | 5,315,830 | ||||||
| Diluted earnings (loss) per share attributable to common stock | $ | (0.35 | ) | $ | 0.66 | |||
| Weighted average common shares outstanding, diluted | 5,348,557 | 5,357,530 | ||||||
| Comprehensive income (loss): | ||||||||
| Net income (loss) | $ | (1,864,873 | ) | $ | 3,513,621 | |||
| Net unrealized loss on marketable investment securities | (3,617 | ) | (17,863 | ) | ||||
| Comprehensive income (loss) | $ | (1,868,490 | ) | $ | 3,495,758 |